Better Care for PFAS Patients Act of 2026

This legislation mandates the periodic issuance of up-to-date clinical guidance on the health effects of per- and polyfluoroalkyl substances (PFAS). It directs the Director of the Agency for Toxic Substances and Disease Registry (ATSDR) to contract with the National Academies of Sciences, Engineering, and Medicine, or another appropriate entity, to assess PFAS health impacts and formulate clinical recommendations.

The agreement requires an initial assessment and recommendations within two years, with updates every five years or more frequently based on scientific developments. This process also includes engaging with PFAS-exposed communities to incorporate their experiences regarding exposure, testing, and clinical follow-up.

Based on these findings, the ATSDR Director must issue, post, and disseminate comprehensive clinical guidance to State and local public health authorities and healthcare professionals. The initial guidance is due within five years of the agreement, with subsequent updates and dissemination occurring every five years or as needed to reflect the latest scientific understanding.